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In the UK there is variation in the treatment of older women with breast cancer, with up to 40% 
receiving primary endocrine therapy (PET), which is associated with inferior survival. Case mix and 
patient choice may explain some variation in practice but clinician preference may also be 
important. 
Methods 
A multicentre prospective cohort study of women aged >70 with operable breast cancer.   Patient 
characteristics (health status, age, tumour characteristics, treatment allocation and decision-making 
preference) were analysed to identify whether treatment variation persisted following case-mix 
adjustment. Expected case-mix adjusted surgery rates were derived by logistic regression using the 
variables age, co-morbidity, tumour stage and grade. Concordance between patients’ preferred and 
actual decision-making style was assessed and associations between age, treatment and decision-
making style calculated.  
Results  
Women (median age 77, range 70-102) were recruited from 56 UK breast units between 2013 and 
2018.  Of 2854/3369 eligible women with oestrogen receptor positive breast cancer, 2354 were 
treated with surgery and 500 with PET. Unadjusted surgery rates varied between hospitals, with 
23/56 units falling outside the 95% confidence intervals on funnel plots. Adjusting for case mix 
reduced, but did not eliminate, this variation between hospitals (10/56 units had practice outside 
the 95% confidence intervals). Patients treated with PET had more patient-centred decisions 
compared to surgical patients (42.2% vs 28.4%, p<0.001).   
Conclusions 
This study demonstrates variation in treatment selection thresholds for older women with breast 
cancer. Health stratified guidelines on thresholds for PET would help reduce variation, although 
patient preference should still be respected.  
 




Older women (>70 years) account for more than a third of new breast cancer diagnoses in the UK 
and have poorer outcomes compared to younger women, with later stage at presentation and 
higher rates of non-standard treatment (1-4). One such treatment is Primary Endocrine Therapy 
(PET), where surgery is omitted in favour of endocrine therapy alone to treat women with oestrogen 
receptor positive (ER+) breast cancer. A Cochrane review comparing PET with surgery in the over 70s 
demonstrated superior rates of local control with surgery but no difference in five year overall 
survival rates (5). However the included studies were flawed by modern standards as some included 
women with ER negative disease and some also included younger, healthy women. More recent 
studies have advocated the use of PET only in the very old or frail (6) and current guidelines state 
that only patients who decline surgery or who are unfit for surgery should be treated this way (7).  In 
addition, a more recent individual patient meta-analysis of the randomised trial data, with longer 
follow-up, conducted by the Early Breast Cancer Trialist’s group, demonstrated significantly 
improved long term (15 years) survival in surgically treated women (8).  
Surgery for all older women is not appropriate and may cause harm if offered to the frailest and 
most comorbid older women.  This was recently demonstrated by a recent study of outcomes of 
nursing home residents with breast cancer in the USA (9).  These frail older women were all treated 
with surgery which resulted in significant morbidity and mortality as well as causing significant 
functional decline.  Surgery may also have a negative impact on quality-of-life due to long term 
adverse events such as lymphoedema and chronic pain.  Therefore in frailer older women, for whom 
life expectancy is limited, PET is potentially the better option.   The issue is determining where this 
threshold sits.    
In the UK there is considerable variation in the use of PET to treat women over 70 with operable 
breast cancer (10), with regional rates varying between 12 and 40% (11,12). A study using 
retrospective registry data has shown that case mix (variation in stage, health, fitness, deprivation 
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levels) does not account for all of this variation (13). This suggests that some of this variation is due 
to individual surgeon or patient preference.   Patient preference for non-surgical therapy is often 
reported as a major factor in determining PET treatment in older patients (14). However previous 
studies examining this have suggested that lower rates of surgery in older patients are unlikely to be 
due to patient choice alone (15).   Variation due to surgeon preference is substantial (16).   
The treatment of older women with operable breast cancer may be considered a preference-
sensitive healthcare decision and so it is important that shared decision-making be employed, with 
patients and healthcare professionals working together to determine the best treatment for that 
individual based on the clinical evidence and the patients’ informed preferences (17-18). However, 
there is some evidence to suggest that not all older patients wish to engage in shared decision-
making, preferring instead to simply receive information (19) and accept a doctor-led treatment 
decision (20-22).  
The present study used prospectively collected detailed data from a large, multi-centre cohort study, 
which examined surgical treatment rates across UK hospitals in older women with operable, ER+ 
breast cancer (before and after adjustment for case-mix). We also investigated associations between 
treatment choice (surgery or PET) and patient decision-making style to determine whether patient 








Ethics approval and research governance approval was obtained (IRAS: 12 LO 1808). All patients gave 
written informed consent or consent was given by a proxy if the patient was cognitively impaired. The 
trial reporting followed the STROBE guidelines for reporting of observational studies (23). 
 
Study Design: 
A prospective, multicentre, comprehensive observational cohort study.   
 
Sites:   
Patients were recruited from 56 breast units in England and Wales (Supplemental Table ST1). 
Supplemental Table ST1.  List of recruiting sites  
 Site Name Local PI 
1 Sheffield Lynda Wyld and Matt Winter 
2 Barnsley Julia Dicks 
3 Doncaster Clare Rogers 
4 Milton Keynes Amanda Taylor 
5 Scunthorpe and Grimsby Rajesh Vijh (Scunthorpe), Jenny Smith (Grimsby) 
6 Leicester Monika Kaushik 
7 Derby Kwok Leung Cheung 
8 East Lancashire Julie Iddon 
9 Harrogate Matthew Adelekan 
10 St Helens and Knowsley Riccardo Audisio 
11 York Rana Nasr (York and Scarborough) 
12 Liverpool Chris Holcombe 
13 Airedale Claire Murphy 
14 Leeds Kieran Horgan 
15 Bradford Rick Linforth 
16 Cardiff Helen Sweetland 
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17 Aneurin Bevan Health Board Simon Waters (Royal Gwent), Theresa Howe (Nevill Hall) 
18 Royal Lancaster Rishi Parmeshwar 
19 Coventry Abigail Tomlins 
20 Grantham Anzors Gvaramadze 
21 Lincoln Anzors Gvaramadze 
22 Pilgrim Anzors Gvaramadze 
23 Hull Peter Kneeshaw 
24 Nottingham Lisa Whisker 
25 Southport Anwar Haq 
26 Leighton Vanessa Pope 
27 Royal Marsden Jenny Rusby 
28 Cheltenham General Sarah Vestey 
29 Guys and St Thomas Michael Douek 
30 Dorset County Caroline Osborne 
31 Mid Essex Sascha Miles-Dua 
32 Mid Yorkshire Jay Naik 
33 Bristol Zoe Winters 
34 Chesterfield Iman Azmy 
35 Rotherham Inder Kumar 
36 Darent Valley Seema Seetharam 
37 Kingston Karyn Shenton 
38 Colchester Mukesh Mukesh 
39 Yeovil Caroline Osborne 
40 Croydon Sanjay Joshi 
41 North Tees Colm Hennessy 
42 South Tees Imtiaz Cheema 
43 Luton and Dunstable Mei-Lin Ah-See 
44 Weston General Rachel Ainsworth 
45 Tameside Stephanie Ridgway 
46 Macclesfield Lisa Barraclough 
47 Wrightington, Wigan and Leigh Angela Power 
48 Birmingham Fiona Hoar 
49 Kings Mill Rebecca Boulton 
50 Wythenshawe Nigel Bundred 
51 Aintree Peter Robson 
52 Brighton Gargi Patel 
53 St Margaret’s Ashraf Patel 
54 St Marys  Steve Parker 
55 Oxford Asha Adwani 






Female patients ≥70 years of age. Primary operable invasive breast cancer (TNM stages: T1-4, N0-2, 
M0).   
 
Exclusion criteria: 
Disease unsuitable for surgery. Previous breast cancer within five years.  
 
Baseline data collection: 
Women were recruited at the time of breast cancer diagnosis and before treatment.   
A baseline comprehensive geriatric assessment was performed using a range of validated tools with 
data collected on age, comorbidities (Charlson comorbidity index; CCI) (24), functional status 
(activities of daily living; ADL (25) and instrumental activities of daily living; IADL (26)), cognitive 
function (using the Mini Mental State Examination; MMSE (27)). Cognitive impairment was defined as 
a MMSE score <24, if they were consented by proxy or if dementia was identified on the CCI. 
Nutritional status was measured using the abridged patient generated subjective global assessment 
(aPBSGA) (28). 
Baseline tumour characteristics were collected, including tumour size, biological subtype, grade and 
nodal status (both clinical, imaging and pathological status). 
Patients’ preferred and actual decision-making styles for their breast cancer treatment were also 
recorded using a validated questionnaire instrument (29,30). The questionnaire instrument uses a five 
point scale for both preferred and actual decision-making styles, ranging from the doctor making all 
decisions, through to the patient making the final decisions (see Supplemental Table ST2). The 
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decision-making preferences questionnaire was applied within 4 weeks of diagnosis and prior to 
treatment. Decision-making styles were then classified into one of three categories: Patient-centred, 
Shared and Doctor-centred (see Supplemental Table ST2). 
Supplemental Table ST2: Classification of decision-making styles. 
 
  
  Patient’s referred decision-
making style 
Actual decision-making style Decision-making 
Classification 
1 I prefer to leave all decisions 
regarding my treatment to my 
doctor 
My doctor made all the 




2 I prefer that my doctor makes 
the final decision about which 
treatment will be used, but 
seriously considers my opinion 
My doctor made the final 
decision about which treatment 
was used, but seriously 
considered my opinion 
3 I prefer that my doctor and I 
share responsibility for deciding 
which treatment is best for me 
My doctor and I shared the 
responsibility for deciding which 
treatment was best for me 
Shared decision-
making 
4 I prefer to make the final 
selection of my treatment after 
seriously considering my 
doctor’s opinion 
I made the final selection of my 
treatment after I had seriously 
considered my doctor’s opinion 
Patient-centred 
decision-making 
5 I prefer to make the final 
selection about which treatment 
I will have 
I made the final selection about 




Primary treatment was dichotomised as surgery or PET. The proportion of patients undergoing 
surgery was calculated for each hospital.  
Multivariable logistic regression was used to estimate the probability of a woman undergoing 
surgical treatment based on patient level factors, including age, Charlson co-morbidity index, 
activities of daily living (ADL), instrumental activities of daily living (IADL), Eastern Cooperative 
Oncology Group (ECOG) performance status, tumour size and grade. Univariate models were first 
built included all variables and the model AIC values were used to determine which variables had 
most predictive importance.  Multivariate models were then formed by adding variables in order of 
importance until the model AIC value ceased to improve.  Further tests adding and removing 
individual covariates and comparing AIC led to a preferred model, which explained but did not over-
fit the data. Missing data on disease characteristics and co-morbidity was handled using the method 
of multiple imputation by chained equations (MICE) (31) to produce 25 imputed data sets and 
combining the results (32).  
Expected rates of surgical treatment were calculated for each hospital by summing the individual 
patient probabilities estimated from the logistic regression model. Risk adjusted rates of surgery 
were produced by dividing the observed rate by the expected rate for each clinician and hospital and 
multiplying this by the national rate (33).  
Both unadjusted and adjusted rates of surgery at hospital level were displayed graphically as funnel 
plots to allow examination of the variability at each level and identification of outlying practice. 
Funnel plots contain two limits; under the hypothesis that treatment choice is randomly determined 
and independent of clinician or hospital, 95% of units would be expected to lie within the inner limits 
(2 standard deviations from the mean) and 99% within the outer limits (3 standard deviations from 
the mean). Hospitals were said to have a Low Surgery rate if they lay below the 95% CI after 
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adjustment for case mix and High Surgery rate if they lay above the 95% CI after adjustment for case 
mix. 
Concordance between preferred and actual decision-making preferences was assessed using Kappa 
and association between treatment, patient characteristics and decision-making style were 
identified using Chi-squared tests. Statistical significance was taken at p<0.05. 
Logistic regressions and multiple imputations were performed using the open source statistical 
programming language R (version 3.0.1), with the remaining data handling and analysis performed in 






Baseline Characteristics  
A total of 3369 women with primary operable breast cancer were recruited to the study between 1st 
February 2013 and 6th June 2018. Of these, 60 patients received treatment that was not obviously 
primary surgery or PET or had inadequate recorded data to make an assessment on their treatment 
and were excluded from the analysis. A further 455 were excluded from the analysis due to having ER 
negative tumours or having insufficient data to draw conclusions about their ER status. The final 
population for analysis included 2854 patients with ER+ tumours, of whom 2354 were treated with 




Figure 1.  Flow diagram for study. 




ER positive cancer N=2854









questionnaire data available 369
Excluded due to ER negative 
cancer 455
Excluded due to treatment that 
was not surgery or PET N=60






The median age of surgical patients in the study was 76 years (range 70-95) and 84 years (70-102) for 
the PET patients. Baseline patient and tumour characteristics are shown in Supplemental Table ST3. 
Supplemental Table ST3: Patient and tumour Characteristics According to Treatment Type 








70-74 years 992 (42.1%) 52 (10.4%) 1044 (36.6%) 
75-79 years 756 (32.1%) 79 (15.8%) 835 (29.3%) 
80-84 years 424 (18.0%) 142 (28.4%) 566 (19.8%) 
85+ years 182 (7.7%) 227 (45.4%) 409 (14.3%) 
Missing 0 0 0 
Cognition 
Normal 1399 (59.4%) 181 (36.2%) 1580 (55.4%) 
Impaired* 232 (9.9%) 73 (14.6%) 305 (10.7%) 
Missing 723 (30.7%) 246 (49.2%) 969 (34.0%) 
Charlson Comorbidity Index (CCI) 
3 891 (37.9%) 41 (8.2%) 932 (32.7%) 
4 529 (22.5%) 87 (17.4%) 616 (21.6%) 
5 457 (19.4%) 100 (20.0%) 557 (19.5%) 
6+ 396 (16.8%) 231 (46.2%) 627 (22.0%) 
Missing 81 (3.4%) 41 (8.2%) 122 (4.3%) 
ECOG Performance Status 
Fully Active (0) 1659 (70.5%) 137 (27.4%) 1796 (62.9%) 
Restricted in strenuous activity (1) 481 (20.4%) 167 (33.4%) 648 (22.7%) 
Fully ambulatory, capable of self-care (2) 68 (2.9%) 67 (13.4%) 135 (4.7%) 
Capable of only limited self-care (3) 31 (1.3%) 75 (15.0%) 106 (3.7%) 
Completely disabled (4) 1 (0.04%) 7 (1.4%) 8 (0.3%) 
Missing 114 (4.8%) 47 (9.4%) 161 (5.6%) 
Tumour size 
0-10mm 538 (22.9%) 50 (10.0%) 588 (20.6%) 
11-20mm 971 (41.2%) 178 (35.6%) 1149 (40.3%) 
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21-30mm 527 (22.4%) 146 (29.2%) 673 (23.6%) 
>30mm 282 (12.0%) 114 (22.8%) 396 (13.9%) 
Missing 36 (1.5%) 12 (2.4%) 48 (1.7%) 
HER2 status 
Negative 1640 (69.7%) 312 (62.4%) 1952 (68.4%) 
Positive 202 (8.6%) 34 (6.8%) 236 (8.3%) 
Inconclusive 70 (3.0%) 14 (2.8%) 84 (2.9%) 
Missing 442 (18.8%) 140 (28.0%) 582 (20.4%) 
Tumour Grade 
I 399 (16.9%) 98 (19.6%) 497 (17.4%) 
II 1475 (62.7%) 329 (65.8%) 1804 (63.2%) 
III 369 (15.7%) 57 (11.4%) 426 (14.9%) 
Missing  111 (4.7%)  16 (3.2%)  127 (4.4%) 
Pre-operative Lymph Node Status 
Negative 2022 (85.9%) 406 (81.2%) 2428 (85.1%) 
Positive 325 (13.8%) 90 (18.0%) 415 (14.5%) 
Missing 7 (0.3%) 4 (0.8%) 11 (0.4%) 
*Impaired cognition = Mini Mental State Examination score <27, known dementia or consultee 
participant. CCI presented here includes age component. 
  
Associations with treatment type 









Table 4: Multivariate Logistic Regression Results (N= 2854) 
 OR of having surgery 95% Confidence 
Intervals 
P value 
Age (per year above 
70) 
0.866 0.847 - 0.886 <0.001 
ECOG PS 1* compared 
to PS 0 
0.556 0.411 - 0.751 <0.001 
ECOG PS 2* compared 
to PS 0 
0.340 0.202 - 0.572 <0.001 
ECOG PS 3* compared 
to PS 0 
0.338 0.153 - 0.745 0.007 
ECOG PS 4* compared 
to PS 0 
0.294 0.023 - 3.699 0.343 
IADL (per increase in 
score) 
1.236 1.086 - 1.405 0.001 
CCI (per increase in 
score) 
0.824 0.758 - 0.892 <0.001 
ADL (per increase in 
score) 
1.087 0.992 - 1.191 0.072 
Size (per mm) 0.988 0.979 - 0.997 0.007 
Grade 2 (compared to 
Grade 1) 
1.453 1.057 - 1.998 0.022 
Grade 3 (compared to 
Grade 1) 
2.607 1.665 - 4.081 <0.001 
*ECOG Performance Status 0: Fully active; ECOG Performance Status 1: Restricted in physically 
strenuous activities; ECOG Performance Status 2: Ambulatory and capable of all self-care; ECOG 
Performance Status 3: Capable of only limited self-care; ECOG Performance Status 4: Completely 
Disabled. 
OR = Odds Ratio; CI = Confidence Interval 
 
Poorer performance status as assessed by the ECOG PS tool was associated with lower rates of 
surgical treatment. Higher rates of co-morbidity (as assessed by the CCI) and functional status (as 
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assessed by ADL and IADL) were associated with lower rates of surgical treatment. Larger tumour 
size was associated with lower surgery rates, whereas patients with grade 2 or 3 tumours were more 
likely to undergo surgery compared to those with grade 1 disease.  
Rates of surgical treatment 
The unadjusted rates of surgery varied substantially between the 56 hospitals (Figure 2(a)) ranging 
from 28.6 % to 100%, with 6 of 56 (10.7%) falling outside the outer 99% limits and 23 of 56 (41.1%) 
falling outside the inner 95% confidence limits on the funnel plots.  The expected number falling 
outside this limit is by defined 1% and 5% respectively. Of the 23 outlying units, 10 had a higher than 
expected rate of surgery and 13 had a lower than expected rate of surgery (i.e. a higher rate of PET). 
Taking account of patient level characteristics and adjusting for case mix (including patient age, 
ECOG performance status, Charlson Comorbidity Index, Activities of Daily Living, Instrumental 
Activities of Daily Living, tumour size, tumour grade) reduced, but did not eliminate, the variation in 
surgery rates between hospitals, with 5 of 56 (8.9%) still falling outside the 99% confidence limits 
and 10 of 56 (17.9%) falling outside the 95% limits on the funnel plot (Figure 2(b)). Of the 10 
persistently outlying units at the 95% level, 2 had a higher than expected rate of surgery and 8 had a 

















Analysis of decision making styles 
Of the study population, 2485/2854 (87.1%) patients had data available to analyse on decision-
making preference, 2097 of these (84.4%) underwent surgery and 388 (15.6%) were treated with 
PET. 
Patients preferred a doctor-centred decision-making style in 912 (36.7%), a shared decision-making 
style in 935 (37.6%) and a patient-centred decision-making style in 638 (25.7%). Patients rated their 
actual decision-making style as doctor-centred in 980 (39.4%), shared in 737 (29.7%) and patient-
centred in 768 (30.9%). Agreement between preferred and actual decision-making style was 73.6% 
(Kappa = 0.60, p<0.001; see figure 3).  
Figure 3: Concordance between patients’ preferred and actual decision-making styles. 
 
Both preferred and actual decision-making styles were associated with final treatment type (see 
table 5). 



















































Patients treated with PET had significantly more patient-centred treatment decisions (42.3%) 
compared to shared (29.9%) or doctor-centred (27.8%); p<0.001.  Whereas patients who underwent 
surgery were more likely to have a doctor-centred (41.6%) treatment decision as opposed to shared 
(29.6%) or patient-centred (28.8%); p<0.001 (table 5). 
Older patients had a significantly higher preference for patient-centred decision making than 
younger patients and this was also reflected in the actual decision type, with the youngest cohort 
having much more doctor-centred treatment decisions (see table 6). 







































































Units that had a high rate of surgery (i.e. a rate higher than the upper 95% confidence limit), after 
adjustment for case mix, had significantly higher rates of doctor-centred actual decision-making 
styles (64.5% vs 30.6%; p<0.001). Conversely, units with a low rate of surgery (i.e. a rate less than the 
lower 95% confidence limit) following adjustment for case mix, had significantly higher rates of 








Table 7: Patients actual decision-making style by hospital surgery rate. 







































In this large prospective cohort study of the treatment of older women breast cancer across 56 units 
in England, 17.5% (500/2854) of ER+ patients were treated with PET, which is lower than figures 
published by similar recent audits; most recently, the National Audit of Breast Cancer in Older 
Patients found that 24% of women aged 70+ years with early ER+ breast cancer were treated with 
PET between 2014 and 2017 (12). This may be because our study missed recruitment of some of the 
older, frailer cohort that would be more like to be treated in this way due to the requirement for 
consented enrolment.   Comparison of the study data with UK national registry data age distribution 
in older cancer patients does show that this study slightly over recruited younger women (70-75) 
and under recruited older women, so the results may not be wholly representative of the picture 
across the UK (34).    
The analysis demonstrates that increasing age at diagnosis is associated with a reduced likelihood of 
receiving surgical treatment which is consistent with other similar studies (1,15, 35-38). Higher levels 
of comorbidity and functional impairment (using ADL, IADL and ECOG performance status) were also 
associated with non-surgical treatment, which is again consistent with other published studies, 
where co-morbidity is often stated as a major reason for choosing PET over surgery (14, 39, 40). 
Tumour factors were also associated with treatment type, with larger tumours being less likely to be 
treated surgically which may represent patients and clinicians trying to avoid more major surgery, 
such as mastectomy and axillary node clearance. These results corroborate and update those found 
by our group in a registry study of 17 129 women aged 70 years and over between 2002 and 2010 
(13). 
There was considerable variation in the rates of surgical treatment across the 56 hospitals and, 
whilst this improved with case-mix adjustment, there was still considerable variation, with 17.9% of 
units remaining outside the 95% limits in funnel plot analysis. Two hospitals had significantly higher 
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and eight hospitals had significantly lower rates of surgery than could be explained by the case mix 
information available.  
This persistence of variation in the treatment of older women with operable, ER+ breast cancer at 
hospital level is due to factors not included in the case-mix adjustment. One possible cause is 
clinician or patient preference for either treatment. These results clearly show that in units with 
higher rates of surgery, there was a significantly higher proportion of doctor-led decision-making 
styles and conversely, in units with higher rates of PET there were significantly more patient-led 
decision-making styles.   
Treatment received was strongly correlated with decision-making style, with patients choosing PET 
having a higher rate of patient-centred decision-making styles compared to those treated surgically. 
This suggests that a significant proportion of women are choosing PET as a means of avoiding 
surgery. It also implies that those units with high surgery rates may be more strongly promoting 
surgery and not taking due consideration of the preferences of women themselves.   What is 
interesting is that a UK survey found that most breast healthcare professionals had a strong view 
that, if given the choice between surgery and PET, most patients would favour surgery (41), which is 
not what our results would suggest. Indeed, patient preference for or refusal of surgery is also often 
stated a reason for treatment with PET (42), however Lavelle and colleagues found, in their cohort of 
800 women over the age of 70, that lower rates of surgery among elderly patients are unlikely to be 
due to patient choice (15). Instead the observed variation may reflect clinician preference and how 
or whether alternative treatment options, such as PET, are presented at all, as was proposed by 
Hamaker and colleagues (43). Current guidelines on the use of PET in the older breast cancer 
population state it should only be used in patients with a short life expectancy (less than 2-3 years), 
or when significant comorbidities preclude surgery, or in patients who refuse surgery (44,45). It is 
left to the treating clinicians’ judgement as to which patients should be offered PET as an alternative 
treatment option to surgery. Comprehensive geriatric assessment may have a role here to help 
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clinicians identify the patients more to benefit from being offered a choice and to support 
communication with patients (46). 
Qualitative research in this older group of patients has suggested that they are more passive 
decision-makers, relying on the advice of healthcare professionals (20, 21, 47). However these 
results clearly show there are a significant proportion of older women who prefer a shared or 
patient-centred decision-making style, in particular in the oldest groups. Previous studies have 
examined the concordance between healthcare professional and patient preference for decision-
making in breast cancer patients and found that their perceptions were often inconsistent with 
patient preference (19). Within this study, around three quarters of patients achieved their decision-
making style, although this means a quarter did not, raising the possibility that they may be making 
choices which are not concordant with their treatment preferences.   One of the factors which 
patients may prioritise highly in this age group is quality-of-life (48) and the maintenance of 
independence (20), both of which may be more highly preserved with PET than surgery (9), but 
valued less by clinicians who may innately prioritise survival metrics.  In younger women the values 
of patients and clinicians are likely to be concordant but less so in older women.  This may account 
for some of the discordancy observed in this study.  There is also a possibility that some clinicians 
taking part may have adjusted their approach to information-giving in the study due to an awareness 
that information on decision-making was being collected. 
Increasing age was associated with more patient-centred decision-making styles, both preferred and 
actual, which may partially explain the higher rates of PET in the oldest old. This may however be 
confounded by surgeons feeling more inclined to stress the importance of surgery in the youngest 
cohort, resulting in a perceived doctor-centred decision by patients in the younger group.  Clinicians 
may also be aware that in the oldest and frailest women, treatment is unlikely to have a huge impact 
on survival as the majority of these women will die of non-breast cancer causes, so choice has less 
impact on survival. 
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This study has allowed us to collect large amounts of complex patient, tumour and treatment data on 
women with operable breast cancer from across the UK.  Additionally, there were some issues with 
data completeness, with cognition and HER2 status subject to the most missing data. The well-
established practice of imputation of data has therefore been used where it was deemed appropriate 
(49). 
This study has identified outlying practice. This is important because patients who are treated with 
PET have been shown to have poorer outcomes compared to those treated with surgery (22, 50-53) 
but also overtreatment of frail older women who are unlikely to die of breast cancer regardless of 
treatment type may suffer unnecessary harms. Continuation of this variability in practice may result 
in a post-code lottery and further guidelines on the management of older women with operable 
breast cancer are needed. Having said that, these results do support the reports that some of the 
use of PET in the older breast cancer population may be due to patient choice which must be 
respected provided appropriate information is provided to patients to make an informed choice. 
There is evidence to suggest that older patients may prioritise quality-of-life over quantity (47,54), 
and clinicians should take this into account when counselling patients about treatment options. 
Shared decision-making suggests that patients should be informed of their treatment options (17) 
and for some older women it may be appropriate to offer PET as an alternative to ‘standard’ surgical 
treatment and allow the patient to decide what is best for them.   Previous work by our group 
supports an individualised approach to treatment decision-making in this group (55) and 
consequently, we have recently developed, validated and trialled a decision aid to support decision 
making for older women facing the choice of surgery or PET (56-59).  This tool is available on line at 
https://agegap.shef.ac.uk/.   The tool displays health, age and fitness stratified survival outcomes for 
women over age 70 with early breast cancer according to whether they have surgery or PET.  We 
hope to adapt this in the near future by adding stratified quality-of life and functional outcomes 
from treatment to ensure women get the information they need and value when making this choice. 
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